Effect of Cross Frequency tACS on Cognitive Control

NCT ID: NCT03800030

Last Updated: 2020-05-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-07

Study Completion Date

2019-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Previous evidence suggests that there are specific frequency bands associated with different aspects of cognitive control. In specific delta (2-4Hz) and beta (15-30Hz) are associated with increased levels of abstraction for learned rules; and theta (5-8Hz) and gamma (30-50Hz) has been associated with increased set-size or number of learned rules. Here we aim to find causal evidence in support of these previous correlational findings by applying cross-frequency transcranial alternating current stimulation (tACS) in the specific frequency bands previously shown to be task-relevant. In a crossover design, we stimulate subjects with either delta-beta or theta-gamma tACS during performance of a hierarchical cognitive control task that manipulates the level of abstraction and set-size of rules that must be learned in order to make the correct button press.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Control Executive Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Healthy participants will receive three waveforms of transcranial alternating current stimulation (tACS). Delta-beta, Theta-gamma, and Sham.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators
Double-blinded. Neither the investigator nor the participants knows which form of stimulation is received.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Theta-gamma, Delta-beta, Sham

Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.

Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS

Group Type EXPERIMENTAL

Theta-gamma tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Theta-gamma, Sham, Delta-beta

Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.

Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS

Group Type EXPERIMENTAL

Theta-gamma tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta, Theta-gamma, Sham tACS

Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.

Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS

Group Type EXPERIMENTAL

Theta-gamma tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta, Sham, Theta-gamma tACS

Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.

Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS

Group Type EXPERIMENTAL

Theta-gamma tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham, Delta-beta, Theta-gamma tACS

Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.

Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS

Group Type EXPERIMENTAL

Theta-gamma tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham, Theta-gamma, Delta-beta tACS

Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.

Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS

Group Type EXPERIMENTAL

Theta-gamma tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Delta-beta tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Sham tACS

Intervention Type DEVICE

NeuroConn technologies, direct current-stimulator plus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Theta-gamma tACS

NeuroConn technologies, direct current-stimulator plus

Intervention Type DEVICE

Delta-beta tACS

NeuroConn technologies, direct current-stimulator plus

Intervention Type DEVICE

Sham tACS

NeuroConn technologies, direct current-stimulator plus

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between the ages of 18 and 35 years
* Able to provide informed consent
* Willing to comply with all study procedures and be available for the duration of the study Speak and understand English

Exclusion Criteria

* Attention Deficit Hyperactivity Disorder (currently under treatment)
* Neurological disorders and conditions, including, but not limited to:
* History of epilepsy
* Seizures (except childhood febrile seizures and electroconvulsive therapy induced seizures) Dementia
* History of stroke
* Parkinson's disease
* Multiple sclerosis
* Cerebral aneurysm
* Brain tumors
* Medical or neurological illness or treatment for a medical disorder that could interfere with study participation (e.g., unstable cardiac disease, malignancy)
* Prior brain surgery
* Any brain devices/implants, including cochlear implants and aneurysm clips
* History or current traumatic brain injury
* (For females) Pregnancy or breast feeding
* Personal or family history of mental/psychiatric disorder (e.g., anxiety, major depressive disorder, schizophrenia, etc.)
* Positive urine test for the following: Marijuana (THC), Cocaine (COC), Phencyclidine (PCP), Amphetamine (AMP), Ecstasy (MDMA), Methamphetamine (Mamp), Opiates (OPI), Oxycodone (OXY), Methadone (MTD), Barbiturates (BAR), Benzodiazepines (BZO), Buprenorphine (BUP), Tricyclic Antidepressants (TCA), Propoxyphene (PPX)
* Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

University of North Carolina, Chapel Hill

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Flavio Frohlich, PhD

Role: PRINCIPAL_INVESTIGATOR

University of North Carolina, Chapel Hill

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of North Carolina, Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Riddle J, McFerren A, Frohlich F. Causal role of cross-frequency coupling in distinct components of cognitive control. Prog Neurobiol. 2021 Jul;202:102033. doi: 10.1016/j.pneurobio.2021.102033. Epub 2021 Mar 16.

Reference Type DERIVED
PMID: 33741402 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01MH101547

Identifier Type: NIH

Identifier Source: secondary_id

View Link

18-0003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Spectral Characteristics of Memory Transformation
NCT05946616 ACTIVE_NOT_RECRUITING NA